John Boozman
John Boozman (Senate) has 15 publicly disclosed stock trades on record, tracked and backtested by CapitolRadar. Updated daily from official disclosure data.
Backtested track record
John Boozman is active in the record from 2025-04-08 to 2026-07-31; 16 distinct tickers; estimated disclosed buy volume of about $120,008 (midpoints of the reported ranges).
Committee assignments: Senate Committee on Agriculture, Nutrition, and Forestry; Senate Committee on Agriculture, Nutrition, and Forestry — Commodities, Derivatives, Risk Management, and Trade; Senate Committee on Agriculture, Nutrition, and Forestry — Conservation, Forestry, Natural Resources, and Biotechnology; Senate Committee on Agriculture, Nutrition, and Forestry — Food and Nutrition, Specialty Crops, Organics, and Research; Senate Committee on Agriculture, Nutrition, and Forestry — Livestock, Dairy, Poultry, and Food Safety; Senate Committee on Agriculture, Nutrition, and Forestry — Rural Development, Energy, and Credit. Committee work is public; CapitolRadar lists it so readers can judge for themselves whether a trade sits close to a member's legislative remit.
Methodology: every disclosed buy is scored on its forward return versus the S&P 500 (SPY) over the next 30 and 90 days. A grade needs at least 5 scored buys.
CapitolRadar analysis
19 trades split across two reported quarters
John Boozman disclosed 19 trades across 16 tickers from April 8, 2025, through July 31, 2026. The record consists of 15 buys and four sells. Nine trades appeared in 2025 Q2, all of them buys. Another 10 trades appeared in 2026 Q3, comprising six buys and four sells. Because the full record spans only 19 transactions and two reported quarters, it is a small sample and does not establish a long-term trading pattern.
$120,008 in estimated buy volume, with two repeat purchases
The disclosed buys represent about $120,008 in estimated volume. That figure uses the midpoints of reported transaction-value ranges, so it is an estimate rather than an exact amount invested. SPYM and MSFT were the most frequently bought securities, with two purchases each. PYPL, CL, UNH, AVGO, EL, and META each had one disclosed buy. Overall, 15 purchases were spread across the record’s 16 tickers, indicating limited repetition among the listed names.
No performance grade is available yet. Zero buys have been scored, while five scored buys are required for a grade. The absence of a grade therefore reflects an insufficient sample for the backtest, not a measured positive or negative result. Congressional transaction reports may also be filed with a disclosure lag of up to 45 days, so reported dates and public availability should not be treated as real-time trading signals.
6 Agriculture Committee assignments provide institutional context
Boozman’s listed assignments are the Senate Committee on Agriculture, Nutrition, and Forestry and five of its panels: Commodities, Derivatives, Risk Management, and Trade; Conservation, Forestry, Natural Resources, and Biotechnology; Food and Nutrition, Specialty Crops, Organics, and Research; Livestock, Dairy, Poultry, and Food Safety; and Rural Development, Energy, and Credit. These assignments provide context for his Senate responsibilities, but the disclosed trading data alone does not show a connection between committee work and any transaction.
Analysis written from the tracked record on 2026-08-23; it is refreshed whenever the underlying numbers change.
Activity by quarter
| Quarter | Disclosed trades | Buys | Sells |
|---|---|---|---|
| 2026 Q3 | 10 | 6 | 4 |
| 2025 Q2 | 9 | 9 | 0 |
Latest disclosed trades
| Date | Ticker | Type | Amount | 30d vs SPY |
|---|---|---|---|---|
| 2026-07-31 | CBOE | sell | $1,001 - $15,000 | — |
| 2026-07-30 | PYPL | buy | $1,001 - $15,000 | — |
| 2026-07-23 | JPM | sell | $1,001 - $15,000 | — |
| 2026-07-23 | SPYM | buy | $1,001 - $15,000 | — |
| 2026-07-09 | APTV | buy | $1,001 - $15,000 | — |
| 2026-07-09 | HD | sell | $1,001 - $15,000 | — |
| 2026-07-02 | TRV | sell | $1,001 - $15,000 | — |
| 2026-07-02 | SPYM | buy | $1,001 - $15,000 | — |
| 2026-07-02 | EL | buy | $1,001 - $15,000 | — |
| 2026-07-02 | CVX | buy | $1,001 - $15,000 | — |
| 2025-04-22 | MSFT | buy | $1,001 - $15,000 | — |
| 2025-04-16 | UNH | buy | $1,001 - $15,000 | — |
| 2025-04-16 | MSFT | buy | $1,001 - $15,000 | — |
| 2025-04-16 | ORCL | buy | $1,001 - $15,000 | — |
| 2025-04-15 | META | buy | $1,001 - $15,000 | — |
| 2025-04-09 | HYG | buy | $1,001 - $15,000 | — |
| 2025-04-08 | CL | buy | $1,001 - $15,000 | — |
| 2025-04-08 | CBOE | buy | $1,001 - $15,000 | — |
| 2025-04-08 | AVGO | buy | $1,001 - $15,000 | — |
Most-bought stocks
SPYM (2) · MSFT (2) · PYPL (1) · CL (1) · UNH (1) · AVGO (1) · EL (1) · META (1)
Frequently asked questions
What stocks did John Boozman buy recently?
Most recently disclosed buys: PYPL (2026-07-30), SPYM (2026-07-23), APTV (2026-07-09), SPYM (2026-07-02). STOCK Act filings can arrive up to 45 days after the trade, so the newest weeks fill in late.
What is John Boozman's most traded stock?
SPYM, with 2 disclosed buys on record, followed by MSFT.
Does John Boozman beat the market?
Not enough scored buys yet to say: a CapitolRadar grade needs at least 5 buys with 30 days of market history after them. The grade appears automatically once the record matures.
How often does John Boozman trade?
About 9.5 disclosed trades per quarter across the last 2 quarters on record, with the busiest quarter at 10 trades.
Where does this data come from?
From official public filings — congressional STOCK Act periodic transaction reports — ingested and backtested daily by CapitolRadar. Amounts are the ranges members are required to report, not exact figures.
Get alerts when trades like these are disclosed. Free account: fantasy portfolio + email alerts. Premium: a 6-hour head start on every signal.
CapitolRadar tracks publicly disclosed trades (STOCK Act filings and SEC Form 4). Disclosures can lag the trade by up to 45 days. Backtests measure past disclosed buys against the S&P 500 and do not predict future results. Everything on this page is impersonal information for your own research — not investment advice.